Item Posts Archive - Page 42 of 1770 - Medivizor
Navigation Menu

Comparing the effects of different antidepressant therapies on depression symptoms in patients with Parkinson’s disease.

Comparing the effects of different antidepressant therapies on depression symptoms in patients with Parkinson’s disease.

Posted by on Nov 22, 2022 in Parkinson's Disease | 0 comments

In a nutshell This study compared the effectiveness of different antidepressant therapies on depression in patients with Parkinson’s disease (PD). The data showed that escitalopram (Cipralex), pramipexole (Mirapex), and repetitive transcranial magnetic stimulation (rTMS) were more effective than routine treatment in these patients. After 4 weeks,...

Read More

Comparing the effects of a Mediterranean versus a low-fat diet in the secondary prevention of cardiovascular events in patients with coronary artery disease.

Comparing the effects of a Mediterranean versus a low-fat diet in the secondary prevention of cardiovascular events in patients with coronary artery disease.

Posted by on Nov 22, 2022 in Coronary artery disease | 0 comments

In a nutshell This study compared the effects of a Mediterranean versus a low-fat diet in the secondary prevention of major cardiovascular events (MACE) in patients with established coronary artery disease (CAD). The data showed that in secondary prevention, the Mediterranean diet was more effective in preventing MACEs compared to a low-fat diet in...

Read More

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Posted by on Nov 22, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) alone or with tiragolumab (MTIG7192A) as a first-line treatment for patients with non-small cell lung cancer (NSCLC). The data showed that tiragolumab plus atezolizumab significantly improved the objective response rate and the survival without...

Read More

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Posted by on Nov 22, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effects on patient-reported outcomes (PROs) of using olaparib (Lynparza) plus abiraterone (Zytiga) versus placebo plus abiraterone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study found that adding olaparib to abiraterone in these patients did not...

Read More

Evaluating the outcomes of single-pass versus multiple-pass during aquablation in patients with urinary symptoms due to benign prostatic hyperplasia.

Evaluating the outcomes of single-pass versus multiple-pass during aquablation in patients with urinary symptoms due to benign prostatic hyperplasia.

Posted by on Nov 22, 2022 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study evaluated the outcomes of single-pass versus multiple-pass during aquablation in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The data showed that treatment with multiple passes during aquablation improved the urinary outcomes compared to a single pass in these patients. Some...

Read More